PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Docket No: O107168

Kenya SHITARA, et al. Allowed: July 22, 2009

Appln. No.: 10/581,413 Group Art Unit: 1644

Confirmation No.: 1999 Examiner: Sharon X, WEN

Filed: June 23, 2006

For: MEDICAMENT COMPRISING RECOMBINANT ANTIBODY AGAINST

CHEMOKINE RECEPTOR CCR4

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP ISSUE FEE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith.

The present Information Disclosure Statement is being filed (without a Statement Under 37 C.F.R § 1.97(e)) after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution in the application (whichever is earlier), and therefore the fee of \$180.00 under 37 C.F.R. § 1.17(p) is being remitted.

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §§ 1.97 and 1.98 U.S. Appln. No.: 10/581,413

Applicants enclose herewith a copy of the Examiner's Report for Australian Patent Application No.: 2004294842, dated August 17, 2009, and a copy of the Document D3, WO 00/042074.

It is noted that documents D1 and D2, (WO 03/018635 and WO 01/064754, respectively) were previously submitted with the Information Disclosure Statement (IDS) filed in the U.S. Patent and Trademark Office on May 17, 2007. Accordingly, copies of these references are not submitted herein.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The U.S. PTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted, /Alan C. Townsley/

Attorney Docket No.: Q107168

SUGHRUE MION, PLLC Telephone: (202) 293-7060 Facsimile: (202) 293-7860

65565 CUSTOMER NUMBER

Date: December 22, 2009

Alan C. Townsley, Ph.D. Registration No. 64,740